Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arginine Veyron is an oral pharmaceutical formulation containing L-arginine hydrochloride as its active ingredient. It is primarily indicated for the adjunctive treatment of difficult digestion (dyspepsia), temporary fatigue (functional asthenia), and congenital hyperammonaemia due to urea cycle disorders[3][4][8]. L-arginine is a semiessential amino acid that serves as a precursor to nitric oxide, facilitating vasodilation and playing a key role in protein synthesis, ammonia detoxification via the urea cycle, and energy metabolism[1][5]. In this formulation, it also supports bile production by the liver and its secretion into the intestine[8]. The product is typically administered orally in liquid form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on arginine veyron.